^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Colon Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Colon Cancer...SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE - CHEMOTHERAPY REGIMENS...Encorafenib + cetuximab (BRAF V600E mutation positive)
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Colorectal Cancer)
    New
    Excerpt:
    ERBITUX® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of...BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)...in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

    Excerpt:
    ...- Adenocarcinoma of the colon or of the upper rectum (supra-peritoneal) considered operable and histologically confirmed, localised, mutated BRAF V600E determined in a biopsy specimen and resectable after CT-scan assessment....
    Trial ID:
    NEORAF